A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer - Milton, Daniel T.; Azzoli, Christopher G.; Heelan, Robert T.; Venkatraman, Ennapadam; Gomez, Jorge E.; Kris, Mark G.; Krug, Lee M.; Pao, William; Rizvi, Naiyer A.; Dunne, Megan; Miller, Vincent A. (Cancer, 2006)
Keywords: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Disease Progression; erlotinib; Erlotinib Hydrochloride; Female; high dose; Humans; lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Male; Medical sciences; Middle Aged; nonsmall cell lung carcinoma; Phase I/II; Pneumology; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Quinazolines - administration & dosage; Quinazolines - adverse effects; Receptor, Epidermal Growth Factor - genetics; Survival Rate; Tarceva; Tumors; Tumors of the respiratory system and mediastinum; Antineoplastic agent; Human; Lung disease; Respiratory disease; Enzyme; Quinazoline derivatives; Transferases; Lung cancer; Enzyme inhibitor; Malignant tumor; non-small cell lung carcinoma; Bronchopulmonary carcinoma; Epidermal growth factor receptor; Phase 1/11; Cancerology; Treatment; Erlotinib; Tarceva; Phase II trial; Phase I trial; Bronchus disease; Protein-tyrosine kinase; High dose; nonsmall cell lung carcinoma